The neuroleptic malignant syndrome (NMS) is an uncommon but dangerous complication of treatment with neuroleptic drugs. First described by Delay and Deniker in 1968, the syndrome is characterized by hyperthermia, muscle rigidity, altered consciousness and autonomic disturbances during neuroleptic treatment. The pathogenesis of the syndrome is unknown. Central dopamine receptor blockade has been implicated both in the pathogenesis of neuroleptic malignant syndrome (Henderson and Wooten, 1981) and in its therapy (Mueller, Vester and Fermaglich, 1983) . A primary defect in skeletal muscle has been suggested in view of similarities in the clinical presentations of neuroleptic malignant syndrome and anaesthetic-induced malignant hyperthermia (Andersson, 1972; Tollefson, 1982; Caroff, Rosenberg and Gerber, 1983; Downey, Rosenberg and Caroff, 1984) . These similarities, including successful treatment with dantrolene (Delacour et al., 1981) , suggest a common pathophysiology underlying both disorders.
In malignant hyperthermia, survivors of the crisis and susceptible family members can be identified by the increased sensitivity of muscle fibres to contracture induced by both caffeine and halothane (Britt et al., 1973; Ellis, Harriman and Currie, 1978) . These in vitro contracture tests are, at present, the most reliable method of identifying individuals susceptible to malignant hyperthermia. The aim of this study was to define if a relationship exists between neuroleptic malig- nant syndrome and malignant hyperthermia susceptibility, by using the halothane and the caffeine contracture tests on survivors of the neuroleptic malignant syndrome.
SUMMARY

PATIENTS AND METHODS
Six survivors of the neuroleptic malignant syndrome were investigated; their clinical histories are summarized in table I. All patients had received neuroleptic drugs before the crisis. Body core hyperthermia in the absence of underlying infection was greater than 38.5 °C. Physical examination revealed neurological disorders, including akinesia, muscle rigidity, autonomic dysfunction and fluctuating level of consciousness. The creatinekinase concentration was always increased and reflected rhabdomyolysis. Acute myoglobinuric renal failure occurred in three patients.
If the patient had received dantrolene sodium, a period of 48 h was allowed to elapse after discontinuing the infusion of the drug before performing the contracture tests. According to the European protocol (Ellis et al., 1984) , the in vitro test involved measuring the tension developed by muscle strips exposed to increasing concentrations of caffeine and halothane in a muscle bath containing Krebs-Ringer solution. The test was performed at 37 °C and the tissue bath was gassed with 5 % carbon dioxide in oxygen. The biopsy was stimulated electrically at a frequency of 0.2 Hz to produce mechanical twitches, thus demonstrating viability.
RESULTS
The results ( fig. 1 ) expressed in accordance with the criteria of the European group defined five of the subjects as MHN (malignant hyperthermia negative). The muscle from patient II developed a contracture of 0.4 g tension on exposure to caffeine 1 mmol litre" 1 ; there was no contracture on exposure to halothane. This subject was denned as MHE (malignant hyperthermia equivocal to caffeine).
DISCUSSION
In malignant hyperthermia, a genetic defect in the sarcoplasmic reticulum accounts for a loss of control of intracellular ionized calcium in the presence of triggering agents, resulting in an increase in intracellular calcium concentration, muscle contracture, metabolic stimulation and changes in permeability. This is reflected in the lower concentrations of caffeine and halothane required to produce contractures in vitro in muscle biopsy specimens from susceptible patients. This provides the basis of a screening test which we have been using in our laboratory. The fact that none of the patients in our study was MHS suggests that there is no pharmacological abnormality in neuroleptic malignant syndrome similar to that found in malignant hyperthermia.
Few results of investigations using halothane and caffeine contracture tests in survivors of the neuroleptic malignant syndrome are to be found in the literature. Caroff, Rosenberg and Gerber (1983) and Downey, Rosenberg and Caroff (1984) studied contractility of muscles in a patient with neuroleptic malignant syndrome and found a contracture of 5.1 g tension on exposure to 1.2 % halothane-a response diagnostic, for those authors, of susceptibility to malignant hyperthermia. Denborough, Collins and Hopkinson (1985) reported the results of an in vitro test in a patient with neuroleptic malignant syndrome. The 1 %-halothane contracture was 0.45 g and the caffeine 2-mmol litre" 1 contracture 0.4 g. The patient's brother also had positive contracture responses. Tollefson (1982) studied contractility of muscles in a patient with neuroleptic malignant syndrome. The tests were negative for both halothane and caffeine, and Tollefson concluded that there was no common peripheral pathophysiological link between neuroleptic malignant syndrome and malignant hyperthermia. It is possible that some of the variations in the results in different centres could be attributed to variations in laboratory procedures.
In the present study, the absence of pharmacological abnormalities in the muscle of patients susceptible to neuroleptic malignant syndrome, and the laboratory differences between neuroleptic malignant syndrome and malignant hyperthermia, suggest that factors other than a muscle BRITISH JOURNAL OF ANAESTHESIA defect may be more important for most patients with neuroleptic malignant syndrome.
